Tumor-targeted inhibition by a novel strategy - mimoretrovirus expressing siRNA targeting the Pokemon gene.

Abstract:

:Pokemon gene has crucial but versatile functions in cell differentiation, proliferation and tumorigenesis. It is a master regulator of the ARF-HDM2-p53 and Rb-E2F pathways. The facts that the expression of Pokemon is essential for tumor formation and many kinds of tumors over-express the Pokemon gene make it an attractive target for therapeutic intervention for cancer treatment. In this study, we used an RNAi strategy to silence the Pokemon gene in a cervical cancer model. To address the issues involving tumor specific delivery and durable expression of siRNA, we applied the Arg-Gly-Asp (RGD) peptide ligand and polylysine (K(18)) fusion peptide to encapsulate a recombinant retrovirus plasmid expressing a siRNA targeting the Pokemon gene and produced the 'mimoretrovirus'. At charge ratio 2.0 of fusion peptide/plasmid, the mimoretrovirus formed stable and homogenous nanoparticles, and provided complete DNase I protection and complete gel retardation. This nanoparticle inhibited SiHa cell proliferation and invasion, while it promoted SiHa cell apoptosis. The binding of the nanoparticle to SiHa cells was mediated via the RGD-integrin α(v)β(3) interaction, as evidenced by the finding that unconjugated RGD peptide inhibited this binding significantly. This tumor-targeting mimoretrovirus exhibited excellent anti-tumor capacity in vivo in a nude mouse model. Moreover, the mimoretrovirus inhibited tumor growth with a much higher efficiency than recombinant retrovirus expressing siRNA or the K(18)/P4 nanoparticle lacking the RGD peptide. Results suggest that the RNAi/RGD-based mimoretrovirus developed in this study represents a novel anti-tumor strategy that may be applicable to most research involving cancer therapy and, thus, has promising potential as a cervical cancer treatment.

authors

Tian Z,Wang H,Jia Z,Shi J,Tang J,Mao L,Liu H,Deng Y,He Y,Ruan Z,Li J,Wu Y,Ni B

doi

10.2174/156800910793357907

subject

Has Abstract

pub_date

2010-12-01 00:00:00

pages

932-41

issue

8

eissn

1568-0096

issn

1873-5576

pii

EPub-Abstract-CCDT-80

journal_volume

10

pub_type

杂志文章
  • FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.

    abstract::Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance to apoptotic stimuli elicited by various anti-tumor drugs. To evaluate a possible relationship between FHIT and TP53 status and response to platinum-analogue reg...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800908785133204

    authors: Cortinovis DL,Andriani F,Livio A,Fabbri A,Perrone F,Marcomini B,Pilotti S,Mariani L,Bidoli P,Bajetta E,Roz L,Sozzi G

    更新日期:2008-08-01 00:00:00

  • The urokinase plasminogen activator system: a target for anti-cancer therapy.

    abstract::The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2). The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a number of physiopathological proces...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800909787314002

    authors: Ulisse S,Baldini E,Sorrenti S,D'Armiento M

    更新日期:2009-02-01 00:00:00

  • Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment.

    abstract::One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, s...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907780618310

    authors: González G,Lage A

    更新日期:2007-05-01 00:00:00

  • EGFR-targeting monoclonal antibodies in head and neck cancer.

    abstract::The epidermal growth factor (EGFR) and its receptor were discovered nearly 40 years ago. Over the past decade interruption of this pathway has been exploited in the treatment of various solid tumors. Antibodies that interfere with ligand binding to and dimerization of the EGFR (and small molecules that inhibit the EGF...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907782418365

    authors: Astsaturov I,Cohen RB,Harari P

    更新日期:2007-11-01 00:00:00

  • Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.

    abstract::Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009618666181010091246

    authors: Liang Z,Lu Z,Zhang Y,Shang D,Li R,Liu L,Zhao Z,Zhang P,Lin Q,Feng C,Zhang Y,Liu P,Tu Z,Liu H

    更新日期:2019-01-01 00:00:00

  • Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?

    abstract::Cancer is a disease in which cellular growth regulatory networks are disrupted. Lesions in well-characterized oncogenes and tumor suppressors often contribute to the dysregulation, but recent work has also uncovered the fundamental importance of enzymes that modulate the acetylation status of chromatin to the initiati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009033481994

    authors: Chen JS,Faller DV,Spanjaard RA

    更新日期:2003-06-01 00:00:00

  • Novel approaches to target pancreatic cancer.

    abstract::Despite remarkable progress that has been made in the recent years in the treatment of gastrointestinal tumors, in particular colorectal cancer, the prognosis of pancreatic cancer remains dismal. Five years after diagnosis almost all patients have died. At early stages of the disease surgery is the only modality to ac...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800911796191079

    authors: Porzner M,Seufferlein T

    更新日期:2011-07-01 00:00:00

  • Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.

    abstract::The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009620666200424145622

    authors: Becker JS,Fathi AT

    更新日期:2020-01-01 00:00:00

  • HER-2 signaling and inhibition in breast cancer.

    abstract::Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800909788166484

    authors: Browne BC,O'Brien N,Duffy MJ,Crown J,O'Donovan N

    更新日期:2009-05-01 00:00:00

  • Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.

    abstract::One of the challenges of cancer therapeutics is to discover targets unique to the tumor cell population. Constitutively activated tyrosine kinases play a role in the malignant phenotype in a number of different cancers. While the kinases may be present in the normal cell, the cancer cell is often dependent upon the ac...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800906779010209

    authors: Ritchie E,Nichols G

    更新日期:2006-12-01 00:00:00

  • MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.

    abstract::MicroRNA-153 (miR-153) is considered to be a tumor regulator. Silencing of miR-153 expression induced apoptosis in breast cancer cells. Data on mechanism suggest that up-regulation of miR- 153 level promotes cell proliferation via the down regulation of the expression of PTEN or FOXO1, which attenuates the proliferati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009615666150225122635

    authors: Chen Y,Feng F,Gao X,Wang C,Sun H,Zhang C,Zeng Z,Lu Y,An L,Qu J,Wang F,Yang Y

    更新日期:2015-01-01 00:00:00

  • The SCF-type E3 Ubiquitin Ligases as Cancer Targets.

    abstract::The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin-proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666151112122231

    authors: Kitagawa K,Kitagawa M

    更新日期:2016-01-01 00:00:00

  • Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.

    abstract::Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and their exact molecular mechanism of action is under investigation. The present study is part of our systemic analysis of interactions of CABA analogs with their molecular targets. These compounds were shown to i...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009614666140821122718

    authors: Mielecki M,Milner-Krawczyk M,Grzelak K,Mielecki D,Krzysko KA,Lesyng B,Priebe W

    更新日期:2014-01-01 00:00:00

  • Transcription factors: molecular targets for prostate cancer intervention by phytochemicals.

    abstract::With increasing incidence of cancer at most of the sites, and growing economic burden and associated psychological and emotional trauma, it is becoming clearer that more efforts are needed for cancer cure. Since most of the chemotherapeutic drugs are non-selective because they are also toxic to the normal cells, new a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907780809732

    authors: Kaur M,Agarwal R

    更新日期:2007-06-01 00:00:00

  • Active-targeted nanotherapy strategies for prostate cancer.

    abstract::Castration-resistant prostate cancer remains incurable and a major cause of mortality worldwide. The absence of effective therapeutic approaches for advanced prostate cancer has led to an intensive search for novel treatments. Emerging nanomedical approaches have shown promising results, in vitro and in vivo, in impro...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800911797264770

    authors: Katsogiannou M,Peng L,Catapano CV,Rocchi P

    更新日期:2011-10-01 00:00:00

  • Novel targeting of apoptosis pathways for prostate cancer therapy.

    abstract::Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patient's age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving t...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009043481623

    authors: Garrison JB,Kyprianou N

    更新日期:2004-02-01 00:00:00

  • Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors.

    abstract::Angiogenesis is a key factor in the carcinogenesis process. In oncological practice, angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors, has been robustly demonstrated to produce clinical benefits and, in specific disease subsets such as colorectal cancer, to extend the overall s...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912800190929

    authors: Bagnasco L,Piras D,Parodi S,Bauer I,Zoppoli G,Patrone F,Ballestrero A

    更新日期:2012-05-01 00:00:00

  • Control of copper status for cancer therapy.

    abstract::Copper is a trace element which is tightly regulated in mammals and lower animals. Disruptions of copper homeostasis in humans are rare and they cause serious disorders such as Wilson's disease and Menke's disease. Copper plays an important role in promoting physiological and malignant angiogenesis. Formation of new b...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800905774574066

    authors: Goodman VL,Brewer GJ,Merajver SD

    更新日期:2005-11-01 00:00:00

  • The expression, function and targeting of haem oxygenase-1 in cancer.

    abstract::Haem oxygenase-1 (HO-1) catalyses the rate-limiting step in haem degradation. All three metabolites resulting from haem degradation (carbon monoxide (CO), biliverdin and free iron) have anti-inflammatory and anti-apoptotic properties. HO-1 is a stress-inducible enzyme found extensively expressed in a vast variety of b...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009614666140320111306

    authors: Hjortsø MD,Andersen MH

    更新日期:2014-01-01 00:00:00

  • Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.

    abstract::Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907781662284

    authors: Warlick ED,Smith BD

    更新日期:2007-09-01 00:00:00

  • A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

    abstract::Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800911795656001

    authors: Cai T,Li X,Ding J,Luo W,Li J,Huang C

    更新日期:2011-06-01 00:00:00

  • Integrins in cancer treatment.

    abstract::Anchorage-independent growth, anoikis resistance, and most steps of metastasis formation are integrin-mediated or -dependent processes, which are characteristics of malignant tumor cells. Acting as oncogenes or tumor suppressor genes, integrins may be involved in the oncogenic transformation of normal cells and their ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800906776056518

    authors: Eble JA,Haier J

    更新日期:2006-03-01 00:00:00

  • Understanding FOXO, new views on old transcription factors.

    abstract::FOXO proteins are evolutionarily conserved transcription factors implicated in several fundamental cellular processes, functioning as end-point for transcriptional programs involved in apoptosis, stress response and longevity. Abrogation of FOXO function is very frequent in human cancer, therefore the mechanisms of re...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800910791054158

    authors: Zanella F,Link W,Carnero A

    更新日期:2010-03-01 00:00:00

  • Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.

    abstract::An apparent low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors is reported; however, the molecular mechanisms have not been elucidated. Angiotensin-II (Ang-II) is well known to be associated with hypertension, as a main peptide of the renin-angiotensin system, and its ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009054629663

    authors: Uemura H,Nakaigawa N,Ishiguro H,Kubota Y

    更新日期:2005-08-01 00:00:00

  • Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

    abstract::Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800908786733450

    authors: Heng DY,Bukowski RM

    更新日期:2008-12-01 00:00:00

  • Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

    abstract::Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membran...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009611313020008

    authors: Grunt TW,Mariani GL

    更新日期:2013-02-01 00:00:00

  • Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

    abstract::Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, en...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800912801784839

    authors: Matsuhashi A,Ohno T,Kimura M,Hara A,Saio M,Nagano A,Kawai G,Saitou M,Takigami I,Yamada K,Okano Y,Shimizu K

    更新日期:2012-07-01 00:00:00

  • Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.

    abstract::Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determi...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/15680096113139990038

    authors: Yao HP,Zhuang CM,Zhou YQ,Zeng JY,Zhang RW,Wang MH

    更新日期:2013-07-01 00:00:00

  • Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.

    abstract::Angiogenesis is crucial for tumor development and progression, and antiangiogenetic therapy represents a promising approach for cancer treatment. Thus, the in-depth understanding of the molecular mechanism(s) regulating angiogenesis, together with the characterization of molecules expressed by endothelial cells and in...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009033481741

    authors: Fonsatti E,Sigalotti L,Arslan P,Altomonte M,Maio M

    更新日期:2003-12-01 00:00:00

  • Role of the RAS in pancreatic cancer.

    abstract::Angiotensin II (Ang II), a main effector peptide of the renin-angiotensin system (RAS), mediates a hormonal action in the maintenance of blood pressure and electrolyte levels, and thus fluid homeostasis. Ang II also mediates paracrine, autocrine and/or intracrine actions in the control of various specific functions of...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800911795538110

    authors: Lau ST,Leung PS

    更新日期:2011-05-01 00:00:00